New use of gliclazide

By using glizide and its derivatives, the problem of insufficient prediction accuracy of existing drugs for treating schizophrenia has been solved, effective prevention and treatment of psychiatric symptoms has been achieved, and the treatment effect of schizophrenia has been significantly improved.

WO2024227384A1PCT designated stage expired Publication Date: 2024-11-07PING AN SHIONOGI CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/082904
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-04
Filing Date
2024-03-21
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

The existing drugs for the treatment of schizophrenia have side effects such as extrapyramidal symptoms, which lead to low drug compliance in patients and limited accuracy in silico prediction, making it difficult to determine the effectiveness of the drug.

Method used

Administered in the form of a pharmaceutical composition or pharmaceutical preparation using glizide and its pharmaceutically acceptable salts or derivatives for the prevention and treatment of schizophrenia and its associated psychiatric symptoms such as delusions, hallucinations, agitations, etc. for the patient.

Benefits of technology

Glizide helps effectively prevent and treat psychiatric symptoms, significantly inhibits the increased spontaneous activity in mice and improves prepulse inhibition of behavioral injury, providing a new medical use to improve the therapeutic effect of schizophrenia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024082904_07112024_PF_FP_ABST
    Figure CN2024082904_07112024_PF_FP_ABST
Patent Text Reader

Abstract

The new use of gliclazide, which particularly relates to the use of gliclazide or a pharmaceutically acceptable salt thereof in the preparation of a drug for the prevention and / or treatment of psychiatric symptoms. The psychotic symptoms are generally associated with schizophrenia and other diseases for which an antipsychotic drug may be used, comprising delusions, hallucinations, thought / speech disorders, agitation, obviously disordered or abnormal movement behavior (comprising catatonia), irritability, etc.
Need to check novelty before this filing date? Find Prior Art

Description

New uses for gliclazide

[0001] Citation of Related Applications

[0002] This invention claims priority to an invention patent application filed in China on May 4, 2023, entitled “New Use of Gliclazide” with application number 202310492617.9. The entire contents of the patent application are incorporated herein by reference. Technical Field

[0003] The present invention belongs to the field of medicine and relates to a new use of gliclazide, in particular to a new use of gliclazide and its derivatives in the field of medicine. Background Art

[0004] It is estimated that there are at least 30 million patients suffering from psychiatric symptoms worldwide (estimates based on WHO projections).

[0005] Currently, drugs for the treatment of schizophrenia have been approved. Although atypical antipsychotics (also known as second-generation antipsychotics) can be used as effective drugs for the treatment of psychotic symptoms, how to balance their safety and effectiveness remains a topic worthy of in-depth study. In particular, in a study of patients taking antipsychotics, more than 20% of cases showed side effects of extrapyramidal symptoms (including dystonia, akathisia, Parkinson's disease-like symptoms, etc.), resulting in low medication compliance in patients, which is one of the important reasons that hinder the completion of treatment (A. Kadakia, BL Brady, C. Dembek, et al., The incidence and economic burden of extrapyramidal symptoms in patients with schizophrenia treated with second generation antipsychotics in a Medicaid population[J], J. Med. Econ., 2022, 25(1):87-98).

[0006] Gliclazide, CAS registration number is 21187-98-4, molecular formula is C 15 H 21 N3O3S is an oral hypoglycemic drug (for example, the trade name of this drug in Japan is GLIMICRON, for which specific information can be found in the Japanese Interview Form; and the trade name in Europe is DIAMICRON, for which specific information can be found in the European SPC).

[0007] US 2022 / 0403469 A1 describes a method for treating schizophrenia, which selects therapeutic drugs based on RNA expression patterns in the blood. In addition, the patent application discloses information on RNA expression patterns in the blood of patients with hallucination symptoms, and predicts known compounds (compounds with drug repurposing potential) that may have therapeutic effects on hallucination symptoms by in silico. However, in general, the accuracy of in silico predictions is limited, and if the drug is not actually administered to animals or humans and evaluated, it is impossible to determine whether the drug is truly effective. In addition, the one-sidedness of the in silico prediction results in US 2022 / 0403469 A1 has been confirmed by relevant literature. For example, clioquinol, one of the compounds with the highest prediction scores in the list, did not improve the symptoms of animal models of psychosis (E.-J.Lee, H.Lee, T.-N.Huang, et al., Trans-synaptic zinc mobilization improves social interaction in two mouse models of autism through NMDAR activation[J], Nat. Commun., 2015, 6:7168).

[0008] Summary of the Invention

[0009] Problems to be solved by the invention

[0010] In view of the technical problems existing in the above-mentioned prior art, the present invention provides the medical use of gliclazide and its derivatives for preventing and / or treating psychotic symptoms associated with schizophrenia and other diseases for which antipsychotic drugs may be used.

[0011] Solutions for solving problems

[0012] <First Aspect>

[0013] The present invention provides use of gliclazide or a pharmaceutically acceptable salt thereof in preparing a medicament for preventing and / or treating psychotic symptoms.

[0014] Furthermore, in the above use, the psychotic symptoms are related to any one or more of schizophrenia and other diseases for which antipsychotic drugs may be used.

[0015] Furthermore, in the above use, the psychotic symptoms are one or more of delusions, hallucinations, disorganized thinking / speech, agitation, significantly disordered or abnormal motor behavior (including catatonia) and irritability.

[0016] Furthermore, in the above use, the psychotic symptoms are one or more of delusion, hallucination and agitation.

[0017] Preferably, in the above-mentioned psychotic symptoms, the delusion includes any one or more of persecution delusion, relationship delusion, body delusion, grandiose delusion, erotomania, nihilistic delusion and jealousy delusion.

[0018] Preferably, in the above-mentioned psychotic symptoms, the hallucinations include any one or more of auditory hallucinations, visual hallucinations, taste hallucinations, olfactory hallucinations, tactile hallucinations and somatosensory hallucinations.

[0019] Preferably, in the above-mentioned psychotic symptoms, the thought / speech disorder includes any one or more of thought disorder and speech disorder.

[0020] Preferably, in the above-mentioned psychotic symptoms, the agitation includes any one or more of increased aimless motor activity, obvious restlessness, aggressiveness and emotional anxiety.

[0021] Preferably, in the above-mentioned psychotic symptoms, the obviously disordered or abnormal motor behavior (including catatonia) comprises one or more of obviously disordered or abnormal motor behavior and catatonia.

[0022] More preferably, in the above-mentioned obviously disordered or abnormal motor behavior (including catatonia), the catatonia includes any one or more of paranoia, mutism, stupor and catatonic excitement.

[0023] Preferably, in the above-mentioned psychotic symptoms, the irritability includes any one or more of annoyance, impatience, anger, sadness, irritability, excitement, aggressiveness and rage.

[0024] At the same time, the present invention provides use of a pharmaceutical composition or pharmaceutical preparation comprising gliclazide or a pharmaceutically acceptable salt thereof in the preparation of a drug for preventing and / or treating psychotic symptoms.

[0025] Furthermore, in the above use, in addition to the gliclazide or a pharmaceutically acceptable salt thereof, the pharmaceutical composition or pharmaceutical preparation further comprises one or more other pharmaceutically active ingredients and / or one or more pharmaceutically acceptable excipients.

[0026] <Second Aspect>

[0027] The present invention provides gliclazide or a pharmaceutically acceptable salt thereof for use in preventing and / or treating psychotic symptoms.

[0028] Furthermore, the psychotic symptoms are associated with any one or more of schizophrenia and other diseases for which antipsychotic drugs may be used.

[0029] Furthermore, the psychotic symptoms are one or more of delusions, hallucinations, disorganized thinking / speech, agitation, markedly disorganized or abnormal motor behavior (including catatonia), and irritability.

[0030] Furthermore, the psychotic symptoms are one or more of delusions, hallucinations and agitation.

[0031] Preferably, in the above-mentioned psychotic symptoms, the delusion includes any one or more of persecution delusion, relationship delusion, body delusion, grandiose delusion, erotomania, nihilistic delusion and jealousy delusion.

[0032] Preferably, in the above-mentioned psychotic symptoms, the hallucinations include any one or more of auditory hallucinations, visual hallucinations, taste hallucinations, olfactory hallucinations, tactile hallucinations and somatosensory hallucinations.

[0033] Preferably, in the above-mentioned psychotic symptoms, the thought / speech disorder includes any one or more of thought disorder and speech disorder.

[0034] Preferably, in the above-mentioned psychotic symptoms, the agitation includes any one or more of increased aimless motor activity, obvious restlessness, aggressiveness and emotional anxiety.

[0035] Preferably, in the above-mentioned psychotic symptoms, the obviously disordered or abnormal motor behavior (including catatonia) comprises one or more of obviously disordered or abnormal motor behavior and catatonia.

[0036] More preferably, in the above-mentioned obviously disordered or abnormal motor behavior (including catatonia), the catatonia includes any one or more of paranoia, mutism, stupor and catatonic excitement.

[0037] Preferably, in the above-mentioned psychotic symptoms, the irritability includes any one or more of annoyance, impatience, anger, sadness, irritability, excitement, aggressiveness and rage.

[0038] Meanwhile, the present invention provides a pharmaceutical composition or pharmaceutical preparation comprising gliclazide or a pharmaceutically acceptable salt thereof, which is used for preventing and / or treating psychotic symptoms.

[0039] Furthermore, in addition to the gliclazide or a pharmaceutically acceptable salt thereof, the pharmaceutical composition or pharmaceutical preparation further comprises one or more other pharmaceutically active ingredients and / or one or more pharmaceutically acceptable excipients.

[0040] <Third Aspect>

[0041] The present invention provides a method for preventing and / or treating psychotic symptoms, comprising the step of administering a preventively and / or therapeutically effective amount of gliclazide or a pharmaceutically acceptable salt thereof to an individual in need thereof.

[0042] Furthermore, in the above method, the psychotic symptoms are related to any one or more of schizophrenia and other diseases for which antipsychotic drugs may be used.

[0043] Furthermore, in the above method, the psychotic symptoms are one or more of delusions, hallucinations, disorganized thinking / speech, agitation, markedly disorganized or abnormal motor behavior (including catatonia), and irritability.

[0044] Furthermore, in the above method, the psychotic symptoms are one or more of delusion, hallucination and agitation.

[0045] Preferably, in the above-mentioned psychotic symptoms, the delusion includes any one or more of persecution delusion, relationship delusion, body delusion, grandiose delusion, erotomania, nihilistic delusion and jealousy delusion.

[0046] Preferably, in the above-mentioned psychotic symptoms, the hallucinations include any one or more of auditory hallucinations, visual hallucinations, taste hallucinations, olfactory hallucinations, tactile hallucinations and somatosensory hallucinations.

[0047] Preferably, in the above-mentioned psychotic symptoms, the thought / speech disorder includes any one or more of thought disorder and speech disorder.

[0048] Preferably, in the above-mentioned psychotic symptoms, the agitation includes any one or more of increased aimless motor activity, obvious restlessness, aggressiveness and emotional anxiety.

[0049] Preferably, in the above-mentioned psychotic symptoms, the obviously disordered or abnormal motor behavior (including catatonia) comprises one or more of obviously disordered or abnormal motor behavior and catatonia.

[0050] More preferably, in the above-mentioned obviously disordered or abnormal motor behavior (including catatonia), the catatonia includes any one or more of paranoia, mutism, stupor and catatonic excitement.

[0051] Preferably, in the above-mentioned psychotic symptoms, the irritability includes any one or more of annoyance, impatience, anger, sadness, irritability, excitement, aggressiveness and rage.

[0052] At the same time, the present invention provides a method for preventing and / or treating psychotic symptoms, comprising the following steps: administering a pharmaceutical composition or pharmaceutical preparation to an individual in need thereof, wherein the pharmaceutical composition or pharmaceutical preparation comprises a preventive and / or therapeutically effective amount of gliclazide or a pharmaceutically acceptable salt thereof.

[0053] Furthermore, in the above method, in addition to the gliclazide or a pharmaceutically acceptable salt thereof, the pharmaceutical composition or pharmaceutical preparation further comprises one or more other pharmaceutically active ingredients and / or one or more pharmaceutically acceptable excipients.

[0054] <Fourth Aspect>

[0055] The present invention provides a pharmaceutical composition or pharmaceutical preparation for preventing and / or treating psychotic symptoms, comprising gliclazide or a pharmaceutically acceptable salt thereof.

[0056] Furthermore, the psychotic symptoms are associated with any one or more of schizophrenia and other diseases for which antipsychotic drugs may be used.

[0057] Furthermore, the psychotic symptoms are one or more of delusions, hallucinations, disorganized thinking / speech, agitation, markedly disorganized or abnormal motor behavior (including catatonia), and irritability.

[0058] Furthermore, the psychotic symptoms are one or more of delusions, hallucinations and agitation.

[0059] Preferably, in the above-mentioned psychotic symptoms, the delusion includes any one or more of persecution delusion, relationship delusion, body delusion, grandiose delusion, erotomania, nihilistic delusion and jealousy delusion.

[0060] Preferably, in the above-mentioned psychotic symptoms, the hallucinations include any one or more of auditory hallucinations, visual hallucinations, taste hallucinations, olfactory hallucinations, tactile hallucinations and somatosensory hallucinations.

[0061] Preferably, in the above-mentioned psychotic symptoms, the thought / speech disorder includes any one or more of thought disorder and speech disorder.

[0062] Preferably, in the above-mentioned psychotic symptoms, the agitation includes any one or more of increased aimless motor activity, obvious restlessness, aggressiveness, emotional anxiety and irritability.

[0063] Preferably, in the above-mentioned psychotic symptoms, the obviously disordered or abnormal motor behavior (including catatonia) comprises one or more of obviously disordered or abnormal motor behavior and catatonia.

[0064] More preferably, in the above-mentioned obviously disordered or abnormal motor behavior (including catatonia), the catatonia includes any one or more of paranoia, mutism, stupor and catatonic excitement.

[0065] Preferably, in the above-mentioned psychotic symptoms, the irritability includes any one or more of annoyance, impatience, anger, sadness, irritability, excitement, aggressiveness and rage.

[0066] Furthermore, in addition to the gliclazide or a pharmaceutically acceptable salt thereof, the pharmaceutical composition or pharmaceutical preparation further comprises one or more other pharmaceutically active ingredients and / or one or more pharmaceutically acceptable excipients.

[0067] Effects of the Invention

[0068] Gliclazide or its derivatives in the present invention are helpful in preventing and / or treating psychotic symptoms such as hallucinations, delusions, agitation, etc. BRIEF DESCRIPTION OF THE DRAWINGS

[0069] FIG1 shows the inhibitory effect of gliclazide on the increase in spontaneous activity of mice induced by MK-801.

[0070] FIG2 shows the improving effect of gliclazide on the impairment of prepulse inhibition behavior induced by MK-801. DETAILED DESCRIPTION

[0071] Definition of terms

[0072] The following describes exemplary embodiments of the present invention in detail. Unless otherwise specified, the term "exemplary" as used herein means "serving as an example, embodiment, or illustration," and any embodiment described as "exemplary" is not necessarily to be construed as superior to other embodiments. Furthermore, to better illustrate the present invention, certain specific details are provided in the following specific examples. Those skilled in the art will appreciate that the present invention can be effectively practiced without these specific details.

[0073] Unless otherwise specified, the numerical values ​​or numerical ranges appearing in the present invention should be understood as including inevitable systematic errors in industrial production; in addition, the numerical range represented by "value A to value B" represents a range including the endpoint values ​​A and B.

[0074] Unless otherwise specified, the units used in this invention are all international standard units.

[0075] Unless otherwise specified, the terms "may" or "could" used in the present invention include both the cases where a certain treatment is performed and the case where a certain treatment is not performed in a subsequent process or step. Accordingly, the terms "optional," "arbitrary," "optionally," or "arbitrarily" indicate that the event or situation described subsequently may but need not occur, and that the description includes both the case where the event or situation occurs and the case where the event or situation does not occur.

[0076] Unless otherwise specified, references to "some specific / preferred embodiments," "other specific / preferred embodiments," "embodiments," etc., herein indicate that the specific elements (e.g., features, structures, and / or properties) described in connection with the embodiments are included in at least one embodiment described herein, and may or may not be present in other embodiments. In addition, those skilled in the art will appreciate that the elements may be combined in various embodiments in any suitable manner.

[0077] Unless otherwise specified, the term "gliclazide or a pharmaceutically acceptable salt thereof" used in the present invention is not limited to specific isomers (stereoisomers, tautomers, etc.). In addition, the term "gliclazide or a pharmaceutically acceptable salt thereof" used in the present invention can be replaced by an isotopic marker.

[0078] In addition, the term "gliclazide or a pharmaceutically acceptable salt thereof" used in the present invention may also be administered as an active metabolite or prodrug thereof.

[0079] In addition, the term "gliclazide or a pharmaceutically acceptable salt thereof" used in the present invention may form a solvate, and the present invention also includes various solvates of this type.

[0080] Unless otherwise specified, the term "pharmaceutically acceptable salt" or "pharmaceutically acceptable salt" as used herein refers to salts that are suitable for use in contact with mammalian (particularly human) tissues without excessive toxicity, irritation, allergic reaction, etc., and are commensurate with a reasonable benefit / risk ratio, within the scope of sound medical judgment. For example, pharmaceutically acceptable salts of amines, carboxylic acids, and other types of compounds (e.g., amides, ureides, etc.) are well known in the art. The salts can be prepared in situ during the final isolation and purification of the compounds of the present invention, or separately by reacting the free base or free acid with a suitable reagent. The pharmaceutically acceptable base addition salts of the present invention include (but are not limited to) alkali metal salts (such as lithium salts, sodium salts, potassium salts, etc.), alkaline earth metal salts (such as magnesium salts, calcium salts, barium salts, etc.), transition metal salts (such as zinc salts, iron salts, etc.), ammonium salts and salts thereof with organic bases (such as trimethylamine, triethylamine, dicyclohexylamine, ethanolamine, diethanolamine, triethanolamine, methylamine, ethylenediamine, pyridine, picoline, quinoline, etc.) or basic amino acids (such as lysine, arginine, histidine, etc.), and the pharmaceutically acceptable base addition salts of the present invention include (but are not limited to) alkali metal salts (such as lithium salts, sodium salts, potassium salts, etc.), alkaline earth metal salts (such as magnesium salts, calcium salts, barium salts, etc.), transition metal salts (such as zinc salts, iron salts, etc.), ammonium salts and salts thereof with organic bases (such as trimethylamine, triethylamine, dicyclohexylamine, ethanolamine, diethanolamine, triethanolamine, methylamine, ethylenediamine, pyridine, picoline, quinoline, etc.) or basic amino acids (such as lysine, arginine, histidine, etc.). Pharmaceutically acceptable acid addition salts include (but are not limited to) salts formed between gliclazide or its derivatives and inorganic acids (such as hydrochloric acid, sulfuric acid, nitric acid, carbonic acid, hydrobromic acid, phosphoric acid, hydroiodic acid, etc.), organic acids (such as formic acid, acetic acid, propionic acid, trifluoroacetic acid, citric acid, lactic acid, tartaric acid, oxalic acid, maleic acid, fumaric acid, succinic acid, mandelic acid, glutaric acid, malic acid, benzoic acid, phthalic acid, ascorbic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, etc.), or acidic amino acids (such as glutamic acid, aspartic acid, etc.).

[0081] Unless otherwise specified, the term "solvate" or "solvate" as used herein refers to a physical association of a compound of the invention with one or more solvent molecules (whether organic or inorganic). This physical association includes hydrogen bonding. In certain circumstances, for example, when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid, the solvate will be capable of isolation. The solvent molecules in the solvate may exist in a regular and / or disordered arrangement. The solvate may contain stoichiometric or non-stoichiometric amounts of solvent molecules. "Solvate" encompasses solution phases and separable solvates. Illustrative examples of solvates include (but are not limited to) hydrates, ethanolates, methanolates, and isopropanolates. Furthermore, solvation methods are well known to those skilled in the art.

[0082] Unless otherwise specified, the term "stereoisomer" as used in the present invention includes geometric isomers, configurational isomers, conformational isomers, etc. Among them, the term "geometric isomer" (especially "cis / trans isomers") refers to isomers containing carbon-carbon or carbon-nitrogen double bonds with E or Z configurations, wherein the term "E" represents that the opposite side of the carbon-carbon or carbon-nitrogen double bond contains a higher order substituent, and the term "Z" represents that the same side of the carbon-carbon or carbon-nitrogen double bond contains a higher order substituent, and the order can be determined using the Cahn-Ingold-Prelog priority rules. The compounds of the present invention can also exist in the form of a mixture of "E" and "Z" isomers.

[0083] Unless otherwise specified, the term "tautomer" as used herein refers to isomers having different energies that can be interconverted via a low energy barrier. If tautomerism is possible (e.g., in solution), a chemical equilibrium of the tautomers can be achieved. For example, proton tautomers (also known as prototropic tautomers) include tautomers that interconvert via proton migration, such as keto-enol isomerization, imine-enamine isomerization, and amide-iminoalcohol isomerization. Valence tautomers include tautomers that interconvert via the reorganization of bonding electrons.

[0084] In addition, the structural formulas described herein include all isomeric forms (e.g., geometric isomers, conformational isomers, tautomers, etc.). Therefore, single stereochemical isomers of the compounds of the present invention or mixtures of their geometric isomers, conformational isomers and / or tautomers are within the scope of the present invention.

[0085] Unless otherwise specified, the term "isotopic derivative" as used herein means that the compounds of the present invention may exist in an isotopically labeled or enriched form, containing one or more atoms whose atomic mass or mass number differs from the atomic mass or mass number of the atom with the greatest natural abundance. Isotopes may be radioactive or non-radioactive. Isotopes commonly used as isotopic labels include, but are not limited to, hydrogen isotopes: 2 H and 3 H; Carbon isotope: 13 C and 14 C; Chlorine isotope: 35 Cl and 37 Cl; Fluorine isotope: 18 F; Iodine isotope: 123 I and 125 I; Nitrogen isotopes: 13 N and 15 N; oxygen isotopes: 15 O. 17 O and 18 O; and sulfur isotopes: 35These isotope-labeled compounds can be used to study the distribution of pharmaceutical molecules in tissues. 2 H and 13 C, because they are easy to label and convenient to detect, they are more widely used.

[0086] Unless otherwise specified, the term "active metabolite" or "active metabolite" as used in the present invention refers to a molecule with certain physiological activity that is produced by the metabolism of a drug. After being metabolized in the subject's body, some drug molecules can continue to have effects on the body. These effects are usually equivalent to or weaker than those of the parent drug molecules, but can still show considerable effects. In addition, some drugs are inactive at the beginning and are designed to produce active pharmaceutical ingredients only after metabolism in the body. Such drugs are called prodrugs. Drugs are designed in this way because prodrugs are more stable during the manufacturing and storage stages, or because prodrugs are better absorbed by the body and have better pharmacokinetic properties.

[0087] Unless otherwise specified, the term "prodrug" as used in the present invention refers to a drug that is converted into the parent drug in vivo. Prodrugs are generally useful and can improve some specific, undesirable physical or biological properties. Physical properties are usually related to solubility (too high or insufficient lipid or water solubility) or stability, while problematic biological properties include too rapid metabolism or poor bioavailability, which themselves may be related to physicochemical properties. For example, they can be bioavailable by oral administration, while the parent drug cannot. The solubility of the prodrug in the pharmaceutical composition is also improved compared to the parent drug. An illustrative example of a prodrug (but not limited to this) can be any compound of the present invention, which is administered as an imide or hydrazine ("prodrug") to facilitate transmission across the cell membrane and enter the cell to be hydrolyzed into an active entity.

[0088] In addition, stereoisomers, tautomers, isotope labels, active metabolites or prodrugs of gliclazide and pharmaceutical compositions or pharmaceutical preparations containing stereoisomers, tautomers, isotope labels, active metabolites or prodrugs of gliclazide also fall within the scope of protection of the present invention.

[0089] In addition, pharmaceutically acceptable salts of stereoisomers, tautomers, isotope-labeled active metabolites or prodrugs of gliclazide, and pharmaceutical compositions or pharmaceutical preparations comprising pharmaceutically acceptable salts of stereoisomers, tautomers, isotope-labeled active metabolites or prodrugs of gliclazide also fall within the scope of protection of the present invention.

[0090] In addition, gliclazide or its stereoisomers, tautomers, isotope-labeled substances, active metabolites or solvates of prodrugs, and pharmaceutical compositions or pharmaceutical preparations comprising gliclazide or its stereoisomers, tautomers, isotope-labeled substances, active metabolites or solvates of prodrugs also fall within the scope of protection of the present invention.

[0091] In addition, solvates of gliclazide or its stereoisomers, tautomers, isotope-labeled substances, active metabolites or prodrugs, and pharmaceutical compositions or pharmaceutical preparations comprising solvates of pharmaceutically acceptable salts of gliclazide or its stereoisomers, tautomers, isotope-labeled substances, active metabolites or prodrugs also fall within the scope of protection of the present invention.

[0092] Unless otherwise specified, the terms "active pharmaceutical ingredient (API)", "pharmaceutically active entity" or "pharmaceutically active molecule" as used herein refer to any substance or mixture of substances used to prepare a pharmaceutical product, and which is capable of exerting pharmacological activity or other direct, relevant effects in the prevention, diagnosis, treatment or alleviation of a disease, or is capable of affecting a subject's body function or structure. Furthermore, in the present invention, pharmaceutical products prepared using active pharmaceutical ingredients (such as gliclazide or its derivatives) are useful, for example, as pharmaceutical products that have the potential to reduce side effects (such as extrapyramidal symptoms).

[0093] Unless otherwise specified, the term "pharmaceutical composition" as used in the present invention refers to a composition comprising a pharmaceutically active ingredient and optionally one or more other pharmaceutically active ingredients and / or optionally one or more pharmaceutically acceptable excipients, wherein the various components of the composition may be physically mixed or isolated. Unless otherwise specified, the term "pharmaceutically acceptable excipient" has a meaning well known to those skilled in the art, for example, including (but not limited to) diluents (or fillers), lubricants, binders, disintegrants, stabilizers, surfactants, flavoring agents, olfactory agents, solvents, cosolvents, pH adjusters, osmotic pressure regulators, etc.

[0094] The pharmaceutical composition of the present invention is administered to a subject in need thereof via either oral or parenteral administration.

[0095] In addition, by appropriately changing the effective amount, dosage form and / or various pharmaceutical additives of the compound of the present invention, the pharmaceutical composition can also be prepared into a pharmaceutical preparation suitable for children, the elderly, critically ill patients or surgical patients.

[0096] Unless otherwise specified, the term "pharmaceutical preparation" as used herein refers to a specific finished pharmaceutical product prepared in a specific dosage form, which contains a specific active pharmaceutical ingredient and, optionally, one or more other active pharmaceutical ingredients and / or, optionally, one or more pharmaceutically acceptable excipients. Unless otherwise specified, the term "dosage form" has a meaning well known to those skilled in the art, including, for example, (but not limited to) tablets, capsules, granules, lozenges, suppositories, ointments, creams, injections, suspensions, mixtures, tinctures, liniments, lotions, inhalants, aerosols, and the like.

[0097] Unless otherwise indicated, the term "treating" as used herein means eliminating, reducing, or ameliorating a disease or condition and / or symptoms associated therewith. Although not excluded, treating a disease or condition does not require the complete elimination of the disease, condition, or symptoms associated therewith. The term "treating" may encompass administering a therapeutically effective amount of a pharmaceutical active ingredient to an individual in need of such treatment. Treatment may be symptomatic, for example, by suppressing symptoms. It may be effective in the short term, may be carried out over the medium term, or may be a long-term treatment, for example, in the context of maintenance therapy.

[0098] Unless otherwise indicated, the term "prevention" as used herein means avoiding the onset of a disease or condition and / or its attendant symptoms in an individual or preventing an individual from acquiring a disease or condition and / or its attendant symptoms, and also includes delaying the onset of a disease and / or its attendant symptoms in an individual, and reducing the risk of an individual developing a disease and / or its attendant symptoms. In addition, the term "prevention" further includes "prophylactic treatment," which refers to reducing the probability of a disease or symptom developing again or recurring in an individual who does not have, but is at risk of or susceptible to the recurrence of a disease or symptom or a recurrence of a previously controlled disease or symptom.

[0099] Unless otherwise specified, the term "effective amount" as used in the present invention refers to a dosage of a drug that can exert an effect consistent with the purpose of prevention and / or treatment or achieve a corresponding effect. For example, the setting of the "effective amount" and the dosage can take into account the patient's age, weight, sex, type and severity of the disease, route of administration, etc. For gliclazide or its derivatives of the present invention, the daily dosage can be, for example, from about 1 mg to about 3000 mg, or from about 1 mg to about 2000 mg, or from about 100 mg to about 2000 mg; the dosage per administration can be, for example, from about 1 mg to about 3000 mg, or from about 1 mg to about 2000 mg, or from about 100 mg to 2000 mg.

[0100] Unless otherwise specified, the term "psychotic symptoms" used in the present invention refers to the Diagnostic and Statistical Manual of Mental Disorders (5th Edition) (abbreviated as DSM-V or DSM-5), which includes: delusions, hallucinations, disorganized thinking / speech, agitation, significantly disordered or abnormal motor behavior (including catatonia) and irritability, but does not include: cognitive impairment.

[0101] Unless otherwise specified, the term "delusions" as used in this invention refers to fixed beliefs, even when there is evidence to the contrary, or refers to false beliefs held in the absence of evidence or proof. The content of delusions may include various themes (e.g., persecutory, relational, somatic, grandiose, etc.). In particular, persecutory delusions (e.g., believing that one is about to be harmed, humiliated, etc. by another person, organization, or other group) are the most common. Relational delusions (e.g., believing that certain gestures, comments, environmental factors, etc. are directed at him or her) are also common. Grandiose delusions (e.g., believing that he or she has extraordinary abilities, wealth, or fame) and erotomania (e.g., mistakenly believing that another person is in love with him or herself) can also be seen. Nihilistic delusions include the belief that a major disaster is about to occur, while somatic delusions are preoccupied ideas focused on health and organ function. Jealousy delusion, also known as Othello syndrome, is a pathological belief that one's spouse or loved one is unfaithful. The sufferer typically does not resort to methods such as hiring a private investigator or installing a home video camera to secretly record their partner to gain evidence of infidelity. Instead, the sufferer gathers trivial supporting evidence (such as disheveled clothing or stained sheets) and draws false inferences to confirm the delusion. The delusion is bizarre, obviously unrealistic, or incomprehensible to individuals of the same culture, and is not based on everyday experience.

[0102] Unless otherwise indicated, the term "hallucinations" as used in the present invention refers to sensation-like experiences when there is no actual external stimulus. This sensation is clear and vivid, has all the elements of normal sensation, and is not under voluntary control. Hallucinations can occur in any sensory form (e.g., auditory hallucinations, visual hallucinations, taste hallucinations, olfactory hallucinations, tactile hallucinations, somatosensory hallucinations, etc.), but in schizophrenia and related disorders, auditory hallucinations (or auditory hallucinations) are the most common. Auditory hallucinations are usually experienced as voices that are different from his or her own thoughts, regardless of whether the voice is familiar or not. Hallucinations must occur in a state of wakefulness, so hallucinations that occur when you are about to fall asleep (before going to bed) or about to wake up (before waking up) are considered normal experiences.

[0103] Unless otherwise indicated, the term "disorganized thinking / speech" as used in the present invention refers to a state of confusion in an individual's thinking or language. Generally, disorganized thinking (formal disorder of thought) refers to illogical, irrelevant or loosely connected ideas that can be inferred from the individual's speech. The individual may jump from one topic to another (derailed thinking or loose associations). The answers to questions may be less relevant or completely irrelevant (contact derailed thinking). The individual's speech may be so severely disorganized that it is completely incomprehensible, and its language organization is illogical, similar to sensory aphasia (incoherent or "a jumble of words"). Because mild speech disorders are common, this symptom must be severe to a certain extent to affect effective communication. If the evaluator and the subject come from different cultural backgrounds, it may be very difficult to assess the severity of the symptom damage. Schizophrenia may have mild thinking or speech disorders before the onset and in the residual period.

[0104] As used herein, and unless otherwise indicated, the term "agitation" refers to a behavioral syndrome characterized by increased aimless motor activity, marked restlessness, aggression, and anxiety.

[0105] Unless otherwise specified, the term "grossly disorganized or abnormal motor behavior (including catatonia)" as used in this invention can be divided into two aspects: (1) Grossly disorganized or abnormal motor behavior may manifest in a variety of behaviors, ranging from childlike "silliness" to unpredictable agitation; individuals may have problems with any goal-directed behavior, leading to difficulties in daily life; (2) Catatonia is a significant decrease in responsiveness to the environment, including resistance to instructions (insults), maintaining a rigid, odd posture, and a complete lack of verbal and motor responses (mutism and catatonia); it also includes purposeless, excessive motor behavior when there is no obvious trigger (catatonia); other characteristics are manifested as stereotyped movements, staring and grimacing, catatonia, and parroting. Although catatonia has historically been associated with schizophrenia, catatonic symptoms are not specific to schizophrenia and may be present in other psychiatric disorders (eg, bipolar or depressive disorders with catatonia) and medical illnesses (catatonia due to other medical conditions).

[0106] Unless otherwise specified, the term "irritability" as used herein refers to an intense but short-lasting emotional disorder, including but not limited to annoyance, impatience, anger, sadness, irritability, excitement, aggression, and rage.

[0107] Unless otherwise indicated, the term "schizophrenia" as used in the present invention adopts the definition of "schizophrenia spectrum and other psychotic disorders" in the Diagnostic and Statistical Manual of Mental Disorders (5th Edition) (abbreviated as DSM-V or DSM-5), which includes schizophrenia, other psychotic disorders and schizotypal (personality) disorder, and these subtypes can be identified by one or more of the following five abnormalities: delusions, hallucinations, disorganized thinking / speech, significantly disorganized or abnormal motor behavior (including catatonia) and negative symptoms.

[0108] Unless otherwise indicated, the term "other diseases for which antipsychotic drugs may be used" as used herein includes, but is not limited to, bipolar and related disorders, autism spectrum disorders, depressive disorders, substance-related and addictive disorders, and dementia.

[0109] Unless otherwise specified, the term "bipolar and related disorders" as used herein refers to a class of mood disorders characterized by both manic or hypomanic episodes and depressive episodes. These disorders typically present in an episodic course, with mania and depression often cycling or alternating, or they may exist in a mixed pattern. Symptoms of each episode often persist for a period of time and adversely affect the patient's daily life and social functioning. These include (but are not limited to) bipolar I disorder, bipolar II disorder, cyclothymic disorder, substance / medication-induced bipolar and related disorders, bipolar and related disorders due to other medical conditions, other specified bipolar and related disorders, and unspecified bipolar and related disorders.

[0110] Unless otherwise indicated, the term "autism spectrum disorder" or "autism spectrum disorder" as used herein refers to persistent deficits in social communication and social interaction in a variety of situations, including deficits in social interaction, deficits in the use of nonverbal communication behaviors in social interaction, and deficits in developing, maintaining, and understanding interpersonal skills. In addition to deficits in social communication, a diagnosis of autism spectrum disorder requires the presentation of restricted, repetitive patterns of behavior, interests, or activities. Because symptoms vary with development and may be masked by compensatory mechanisms, diagnostic criteria may be met based on previous information, but the current clinical manifestations must cause significant impairment.

[0111] Unless otherwise specified, the term "depressive disorder" as used in the present invention refers to a class of mood disorders characterized by depressed mood, including (but not limited to) disruptive mood disorders, major depressive disorder (including major depressive episodes), persistent depressive disorder (dysthymia), premenstrual dysphoric disorder, substance / medication-induced depressive disorder, depressive disorder due to other medical diseases, and other specified and unspecified depressive disorders.

[0112] Unless otherwise specified, the term "substance-related and addictive disorders" as used in this invention refers to a group of physiological, behavioral and cognitive symptoms, including substance-related disorders (including but not limited to alcohol-related disorders, caffeine-related disorders, cannabis-related disorders, hallucinogen-related disorders, inhalant-related disorders, opioid-related disorders, sedative-hypnotic or anxiolytic-related disorders, stimulant-related disorders, tobacco-related disorders, other or unknown substance-related disorders) and non-substance-related disorders (including gambling disorder).

[0113] Unless otherwise specified, the term "dementia" as used in the present invention refers to a syndrome with acquired cognitive impairment as the core, which leads to a significant decline in the patient's daily living ability, learning ability, work ability and social interaction ability. The patient's cognitive impairment involves memory, learning, orientation, understanding, judgment, calculation, language, visual-spatial function, analysis and problem-solving abilities. In DSM-5, dementia is described as a "neurocognitive disorder". Dementia can be divided into degenerative dementia and non-degenerative dementia. The former mainly includes Alzheimer's disease (AD), Lewy body dementia (DLB), Parkinson's disease dementia (PDD) and frontotemporal lobar degeneration (FTLD).

[0114] Medical uses of gliclazide

[0115] First, the present invention provides a new use of gliclazide or its derivatives in the pharmaceutical field.

[0116] Specifically, the present invention provides the use of gliclazide or its stereoisomers, tautomers, isotope-labeled, active metabolites or prodrugs, or pharmaceutically acceptable salts of gliclazide or its stereoisomers, tautomers, isotope-labeled, active metabolites or prodrugs, or solvates of gliclazide or its stereoisomers, tautomers, isotope-labeled, active metabolites or prodrugs in the preparation of a medicament for preventing and / or treating psychotic symptoms.

[0117] In some embodiments, the psychotic symptoms may be associated with one or more of schizophrenia and any other disorders for which antipsychotic drugs may be used.

[0118] In some specific embodiments, the psychotic symptom can be at least associated with, or only associated with, schizophrenia.

[0119] In some specific embodiments, the psychotic symptoms may be associated with at least one other condition for which antipsychotic drugs may be used, or may be associated only with other conditions for which antipsychotic drugs may be used.

[0120] In some specific embodiments, the psychotic symptom can be at least associated with, or only associated with, bipolar and related disorders.

[0121] In some specific embodiments, the psychotic symptom can be at least associated with, or only associated with, an autism spectrum disorder.

[0122] In some specific embodiments, the psychotic symptom can be at least associated with, or only associated with, a depressive disorder.

[0123] In some embodiments, the psychotic symptom can be at least associated with a substance-related and addictive disorder, or can be associated only with a substance-related and addictive disorder.

[0124] In some specific embodiments, the psychotic symptoms may be at least associated with dementia (such as Alzheimer's disease, Parkinson's disease, etc.), or only associated with dementia (such as Alzheimer's disease, Parkinson's disease, etc.).

[0125] In some embodiments, the psychotic symptoms can include a variety of specific manifestations, such as one or more of delusions, hallucinations, disorganized thoughts / speech, agitation, markedly disorganized or abnormal motor behavior (including catatonia), and irritability.

[0126] In some specific embodiments, the psychotic symptoms can include delusions, or can be solely delusions.

[0127] In some more specific embodiments, the delusion may include multiple specific manifestations, for example, any one or more of persecutory delusion, relational delusion, somatic delusion, grandiose delusion, erotomania, nihilistic delusion, and jealousy delusion.

[0128] In more specific embodiments, the delusion can include, or be solely, a persecutory delusion.

[0129] In more specific embodiments, the delusion can include delusions of reference, or can be solely delusions of reference.

[0130] In more specific embodiments, the delusions can include somatic delusions, or can be solely somatic delusions.

[0131] In more specific embodiments, the delusion can include, or be solely, a grandiose delusion.

[0132] In more specific embodiments, the delusion can include, or be solely, an erotomania.

[0133] In some more specific embodiments, the delusion can include, or be solely, a nihilistic delusion.

[0134] In more specific embodiments, the delusions can include, or be solely, delusions of jealousy.

[0135] In some specific embodiments, the psychotic symptoms may include hallucinations, or may be solely hallucinations.

[0136] In some more specific embodiments, the hallucination may include multiple specific manifestations, for example, any one or more of auditory hallucinations, visual hallucinations, taste hallucinations, olfactory hallucinations, tactile hallucinations, and somatosensory hallucinations.

[0137] In some more specific embodiments, the hallucinations can include auditory hallucinations, or be solely auditory hallucinations.

[0138] In some more specific embodiments, the hallucinations can include visual hallucinations, or can be solely visual hallucinations.

[0139] In some more specific embodiments, the hallucinations can include taste hallucinations, or can be solely taste hallucinations.

[0140] In some more specific embodiments, the hallucinations can include olfactory hallucinations, or can be solely olfactory hallucinations.

[0141] In some more specific embodiments, the hallucination can include a tactile hallucination, or can be solely a tactile hallucination.

[0142] In some more specific embodiments, the hallucination can include a somatosensory hallucination, or can be solely a somatosensory hallucination.

[0143] In some specific embodiments, the psychotic symptoms may include disorganized thinking / speech, or only disorganized thinking / speech.

[0144] In some more specific embodiments, the thought / speech disorder may include multiple specific manifestations, for example, any one or more of thought disorder and speech disorder.

[0145] In more specific embodiments, the thought / speech disorder can include disordered thinking, or can be just disordered thinking.

[0146] In more specific embodiments, the thought / speech disturbance can include speech disturbance, or can be only speech disturbance.

[0147] In some specific embodiments, the psychotic symptom can include agitation, or can be solely agitation.

[0148] In some more specific embodiments, the agitation may include a variety of specific manifestations, such as any one or more of increased aimless motor activity, marked restlessness, aggression, and emotional anxiety.

[0149] In more specific embodiments, the agitation can include, or is solely, an untargeted increase in motor activity.

[0150] In some more specific embodiments, the agitation can include noticeable restlessness, or simply noticeable fidgeting.

[0151] In some more specific embodiments, the agitation can include being aggressive, or simply being aggressive.

[0152] In some more specific embodiments, the agitation can include emotional anxiety, or can be solely emotional anxiety.

[0153] In some specific embodiments, the psychotic symptoms can include, or consist solely of, significantly disorganized or abnormal motor behavior (including catatonia).

[0154] In some more specific embodiments, the significantly disordered or abnormal motor behavior (including catatonia) may include multiple specific manifestations, for example, one or more of significantly disordered or abnormal motor behavior and catatonia.

[0155] In some more specific embodiments, the significantly disturbed or abnormal motor behavior (including catatonia) can include significantly disturbed or abnormal motor behavior, or can be simply significantly disturbed or abnormal motor behavior.

[0156] In some more specific embodiments, the significantly disturbed or abnormal motor behavior (including catatonia) can include catatonia, or can simply be catatonia.

[0157] In some further specific embodiments, the catatonia may include multiple specific manifestations, for example, any one or more of apathy, mutism, stupor, and catatonia.

[0158] In some further specific embodiments, the catatonia can include, or only include, perversity.

[0159] In some further specific embodiments, the catatonia can include mutism, or can be solely mutism.

[0160] In some further specific embodiments, the catatonia can include catatonia, or just catatonia.

[0161] In some further specific embodiments, the catatonia can include catatonic agitation, or can be simply catatonic agitation.

[0162] In some specific embodiments, the psychotic symptom can include irritability, or just irritability.

[0163] In some more specific embodiments, the irritability can include annoyance, or simply annoyance.

[0164] In some more specific embodiments, the irritability can include impatience, or simply impatience.

[0165] In some more specific embodiments, the irritability can include anger, or simply anger.

[0166] In some more specific embodiments, the irritability can include sadness, or simply sadness.

[0167] In some more specific embodiments, the irritability can include being angry, or simply being angry.

[0168] In some more specific embodiments, the irritability can include agitation, or simply agitation.

[0169] In more specific embodiments, the irritability can include being aggressive, or simply being aggressive.

[0170] In some more specific embodiments, the irritability can include losing one's temper, or simply losing one's temper.

[0171] In addition to existing in the original form such as a monomeric compound or a mixture of monomeric compounds, gliclazide or its derivatives can also be further prepared into pharmaceutical compositions or pharmaceutical preparations containing them (especially pharmaceutical compositions or pharmaceutical preparations for preventing and / or treating psychotic symptoms). Therefore, the present invention also provides the use of pharmaceutical compositions or pharmaceutical preparations containing gliclazide or its stereoisomers, tautomers, isotope-labeled, active metabolites or prodrugs, or pharmaceutically acceptable salts of gliclazide or its stereoisomers, tautomers, isotope-labeled, active metabolites or prodrugs, or solvates of gliclazide or its stereoisomers, tautomers, isotope-labeled, active metabolites or prodrugs in the preparation of drugs for preventing and / or treating psychotic symptoms.

[0172] In some specific embodiments, the pharmaceutical composition or pharmaceutical preparation may further comprise one or more other pharmaceutically active ingredients and / or one or more pharmaceutically acceptable excipients.

[0173] In some more specific embodiments, the pharmaceutical composition or pharmaceutical formulation may further comprise (or may only comprise) one or more other optional pharmaceutically active ingredients.

[0174] In some more specific embodiments, the pharmaceutical composition or pharmaceutical preparation may further comprise (or may only comprise) one or more optional pharmaceutically acceptable excipients.

[0175] In some specific embodiments, the pharmaceutical composition or pharmaceutical preparation may further comprise (or may only comprise) one or more other pharmaceutically active ingredients and one or more pharmaceutically acceptable excipients.

[0176] In some specific embodiments, the gliclazide or its stereoisomer, tautomer, isotopically labeled, active metabolite or prodrug, or a pharmaceutically acceptable salt of gliclazide or its stereoisomer, tautomer, isotopically labeled, active metabolite or prodrug, or a solvate of gliclazide or its stereoisomer, tautomer, isotopically labeled, active metabolite or prodrug is the only pharmaceutically active ingredient in the drug.

[0177] Secondly, the present invention provides a new medical use of gliclazide or its derivatives.

[0178] Specifically, the present invention provides gliclazide or its stereoisomers, tautomers, isotope-labeled, active metabolites or prodrugs, or pharmaceutically acceptable salts of gliclazide or its stereoisomers, tautomers, isotope-labeled, active metabolites or prodrugs, or solvates of gliclazide or its stereoisomers, tautomers, isotope-labeled, active metabolites or prodrugs, for use in preventing and / or treating psychotic symptoms.

[0179] In some specific embodiments, the psychotic symptoms have the same meanings as the psychotic symptoms described above in the novel use in the pharmaceutical field.

[0180] In addition to existing in the original form such as a monomeric compound or a mixture of monomeric compounds, gliclazide or its derivatives can also be further prepared into pharmaceutical compositions or pharmaceutical preparations containing them. Therefore, the present invention also provides pharmaceutical compositions or pharmaceutical preparations containing gliclazide or its stereoisomers, tautomers, isotope-labeled substances, active metabolites or prodrugs, or pharmaceutically acceptable salts of gliclazide or its stereoisomers, tautomers, isotope-labeled substances, active metabolites or prodrugs, or solvates of gliclazide or its stereoisomers, tautomers, isotope-labeled substances, active metabolites or prodrugs, for use in preventing and / or treating psychotic symptoms.

[0181] In some specific embodiments, the pharmaceutical composition or pharmaceutical preparation has the same meaning as the pharmaceutical composition or pharmaceutical preparation described above in the novel use in the pharmaceutical field.

[0182] In some specific embodiments, the gliclazide or its stereoisomer, tautomer, isotope-labeled, active metabolite or prodrug, or the pharmaceutically acceptable salt of the gliclazide or its stereoisomer, tautomer, isotope-labeled, active metabolite or prodrug, or the solvate of the gliclazide or its stereoisomer, tautomer, isotope-labeled, active metabolite or prodrug is used alone or as the sole active pharmaceutical ingredient.

[0183] Finally, the present invention provides a new use of gliclazide or its derivatives in the field of disease prevention and treatment methods.

[0184] Specifically, the present invention provides a method for preventing and / or treating psychotic symptoms, comprising the steps of administering a preventively and / or therapeutically effective amount of gliclazide or its stereoisomers, tautomers, isotope-labeled, active metabolites or prodrugs, or a pharmaceutically acceptable salt of gliclazide or its stereoisomers, tautomers, isotope-labeled, active metabolites or prodrugs, or a solvate of gliclazide or its stereoisomers, tautomers, isotope-labeled, active metabolites or prodrugs to an individual in need thereof.

[0185] In some specific embodiments, the subject in need thereof can include vertebrates (eg, fish, amphibians, reptiles, birds, mammals, etc.), or only vertebrates.

[0186] In some more specific embodiments, the individual in need thereof can include mammals (e.g., Marsupiales, Insectivoras, Carnivora, Chiroptera, Primates, Perissodactyla, Artiodactyla, etc.), or only mammals.

[0187] In some more specific embodiments, the individuals in need thereof may include primates (e.g., loris, lemurs, aye-aye, tarsiers, capuchins, marmosets, monkeys, gibbons, hominins, etc.), or only primates.

[0188] In some further specific embodiments, the individual in need thereof can include hominins (eg, orangutans, gorillas, chimpanzees, humans, etc.), or only hominins.

[0189] In some further specific embodiments, the individual in need thereof can include humans (eg, Homo sapiens), or can be solely humans (eg, Homo sapiens).

[0190] In some specific embodiments, the psychotic symptoms have the same meanings as the psychotic symptoms described above in the novel use in the pharmaceutical field.

[0191] In addition to existing in the original form such as a monomeric compound or a mixture of monomeric compounds, gliclazide or its derivatives can also be further prepared into a pharmaceutical composition or pharmaceutical preparation containing the same. Therefore, the present invention also provides a method for preventing and / or treating psychotic symptoms, which comprises the following steps: administering the pharmaceutical composition or pharmaceutical preparation to an individual in need thereof, wherein the pharmaceutical composition or pharmaceutical preparation comprises gliclazide or its stereoisomers, tautomers, isotope-labeled, active metabolites or prodrugs, or a pharmaceutically acceptable salt of gliclazide or its stereoisomers, tautomers, isotope-labeled, active metabolites or prodrugs, or a solvate of gliclazide or its stereoisomers, tautomers, isotope-labeled, active metabolites or prodrugs.

[0192] In some specific embodiments, the pharmaceutical composition or pharmaceutical preparation has the same meaning as the pharmaceutical composition or pharmaceutical preparation described above in the novel use in the pharmaceutical field.

[0193] In some specific embodiments, the gliclazide or its stereoisomer, tautomer, isotopically labeled, active metabolite or prodrug, or a pharmaceutically acceptable salt of the gliclazide or its stereoisomer, tautomer, isotopically labeled, active metabolite or prodrug, or a solvate of the gliclazide or its stereoisomer, tautomer, isotopically labeled, active metabolite or prodrug is administered to the individual in need thereof as the sole active pharmaceutical ingredient.

[0194] The present invention is further described below with reference to specific examples. The experimental methods in the following examples, where specific conditions are not specified, are generally based on conventional conditions or conditions recommended by the manufacturer. In addition, any methods and materials similar or equivalent to those described herein can be applied to the methods of the present invention.

[0195] Efficacy evaluation based on MK-801 mouse model

[0196] 1. The MK-801 model, a common non-clinical evaluation system for assessing the improvement of psychiatric symptoms, was used to evaluate the inhibitory effect of gliclazide on the increase in spontaneous behavior induced by MK-801 in mice.

[0197] 1.1 Experimental Materials

[0198] 1.1.1 Animals

[0199] C57BL / 6J mice, 7 weeks old, male.

[0200] Before the experiment, the mice were allowed to acclimate to the environment for one week and each mouse was given a health check, including an assessment of its coat, limbs, and mouthparts, and an inspection of each mouse's posture and movements for any abnormal signs.

[0201] 1.1.2 Medicines

[0202] Methylcellulose;

[0203] MK-801 (also known as Dizocilpine);

[0204] Gliclazide.

[0205] 1.2 Experimental steps

[0206] 1.2.1 Drug preparation

[0207] 1.2.1.1 Preparation of MK-801 solution

[0208] Weigh an appropriate amount of MK801 into a clean test tube, then add an appropriate amount of normal saline. Sonicate and vortex until the solution becomes clear. The concentration of this solution is 0.2-0.3 mg / mL and store at -20°C until use. Transfer an appropriate amount of the MK801 solution to another clean test tube and dilute with an appropriate amount of normal saline to a concentration of 0.02-0.03 mg / mL. When administering (e.g., intraperitoneally), the dose is 10 mL / kg.

[0209] 1.2.1.2 Preparation of gliclazide solution

[0210] Weigh an appropriate amount of gliclazide into a clean test tube, then add an appropriate amount of 0.5% w / v methylcellulose aqueous solution, sonicate, and vortex until the solution becomes clear. Set up in parallel three times to prepare gliclazide solutions with concentrations of 8 mg / mL, 16 mg / mL, and 32 mg / mL, respectively. When administered (e.g., orally or by gavage), the dose is 10 mL / kg, corresponding to 80 mg / kg, 160 mg / kg, and 320 mg / kg for the low, medium, and high doses of gliclazide groups, respectively.

[0211] 1.2.2 Medication and Effect Monitoring

[0212] Mice were induced by intraperitoneal injection of MK-801 solution (dosage: 0.2-0.3 mg / kg body weight), and the increase in the amount of spontaneous behavior of the mice was measured (this parameter can be used as a behavioral indicator of psychotic symptoms).

[0213] 60 minutes before MK-801 administration, mice in the negative control group and the gliclazide low-, medium-, and high-dose groups (8 mice in each group) were orally administered with 0, 80, 160, and 320 mg / kg body weight of gliclazide solution, respectively. The increase in spontaneous behavior of mice in each group was measured within 10 minutes between 10 and 20 minutes after MK-801 administration.

[0214] 1.3 Experimental Results

[0215] The experimental results shown in FIG1 (*** indicates p<0.001 compared with the negative control group, using the Kruskal-Wallis test and the subsequent Conover test) show that gliclazide can significantly inhibit the increase in spontaneous behavior of mice induced by MK-801.

[0216] 2. Gliclazide improves prepulse inhibition behavior impairment

[0217] Currently, it is known that psychotic symptoms associated with schizophrenia are associated with cognitive function. Accordingly, the present invention verifies the effect of gliclazide on impaired sensorimotor gating in the MK-801 mouse model.

[0218] 2.1 Experimental Materials

[0219] 2.1.1 Animals

[0220] Same as item 1.1.1.

[0221] 2.1.2 Medicines

[0222] Same as item 1.1.2.

[0223] 2.2 Experimental steps

[0224] 2.2.1 Drug preparation

[0225] 2.2.1.1 Preparation of MK-801 solution

[0226] Same as item 1.2.1.1.

[0227] 2.2.1.2 Preparation of gliclazide solution

[0228] Same as item 1.2.1.2.

[0229] 2.2.2 Medication and Effect Monitoring

[0230] 60 minutes before MK-801 administration, mice in the sham-operated group, negative control group, and low-, medium-, and high-dose groups (8 mice in the sham-operated group and 10 mice in each of the other four groups) were orally administered 0, 0, 80, 160, and 320 mg / kg body weight of gliclazide solution. Then, the negative control group and low-, medium-, and high-dose groups were intraperitoneally administered with MK-801 solution (dosage of 0.2-0.3 mg / kg body weight), and the sham-operated group was intraperitoneally administered with the same volume of normal saline. 20 minutes after administration, the sensorimotor gating function of the mice was measured using the pre-pulse inhibition of the acoustic startle reflex evaluation system.

[0231] 2.2.3 Data Analysis

[0232] Pre-pulse inhibition (PPI) was calculated using the following formula: (startle response when pre-pulse sound stimulation was given) / (startle response when no pre-pulse sound stimulation was given)×100%.

[0233] 2.3 Experimental Results

[0234] The experimental results shown in Figure 2 (* indicates p < 0.05 compared to the negative control group) demonstrate that gliclazide ameliorates the impairment of prepulse inhibition caused by MK-801, and this improvement is dose-dependent within a certain range. Furthermore, the improvement in the high-dose gliclazide group (320 mg / kg) was more significant compared to the negative control group, and was roughly comparable to the results in the sham-operated group.

[0235] The above descriptions are intended to be illustrative, non-exhaustive, and non-exhaustive embodiments of the present invention, and the present invention is not limited to the specific embodiments disclosed. Many modifications and variations will be apparent to those skilled in the art without departing from the scope and spirit of the described specific embodiments and are within the scope of the present invention.

Claims

1. Use of gliclazide or a pharmaceutically acceptable salt thereof in the preparation of a medicament for preventing and / or treating psychotic symptoms.

2. The use according to claim 1, characterized in that The psychotic symptoms are associated with one or more of schizophrenia and any other disorders for which antipsychotic drugs may be used.

3. The use according to claim 1 or 2, characterized in that: The psychotic symptoms are any one or more of delusions, hallucinations, disorganized thinking / speech, agitation, markedly disorganized or abnormal motor behavior (including catatonia), and irritability.

4. The use according to claim 3, characterized in that The psychotic symptoms are any one or more of delusions, hallucinations and agitation.

5. The use according to any one of claims 1 to 4, characterized in that The gliclazide or a pharmaceutically acceptable salt thereof is the only active pharmaceutical ingredient in the drug.

6. Use of a pharmaceutical composition or pharmaceutical preparation comprising gliclazide or a pharmaceutically acceptable salt thereof in the preparation of a medicament for preventing and / or treating psychotic symptoms, wherein the pharmaceutical composition or pharmaceutical preparation further comprises one or more other pharmaceutically active ingredients and / or one or more pharmaceutically acceptable excipients.

7. The use according to claim 6, characterized in that The psychotic symptoms are associated with one or more of schizophrenia and any other disorders for which antipsychotic drugs may be used.

8. The use according to claim 6 or 7, characterized in that The psychotic symptoms are any one or more of delusions, hallucinations, disorganized thinking / speech, agitation, markedly disorganized or abnormal motor behavior (including catatonia), and irritability.

9. The use according to claim 8, characterized in that The psychotic symptoms are any one or more of delusions, hallucinations and agitation.

10. The use according to any one of claims 6 to 9, characterized in that The gliclazide or a pharmaceutically acceptable salt thereof is the only active pharmaceutical ingredient in the drug.

Citation Information

Patent Citations

  • Application of combination of Sur1 inhibitor and crocetin or pharmaceutically acceptable salt thereof as neuroprotective agent

    CN113332437A

  • Treatment of Insulin Resistance / Metabolic Syndrome to Alleviate the Risks of Dementia

    US20090088367A1

  • Treatment of Alzheimer's Disease Using Compounds that Reduce the Activity of Non Selective Ca Activated ATP- Sensitive Cation Channels Regulated by SUR1 Receptors

    US20100056444A1

  • Inhibitor of TRPM-4 ion channel for treating or preventing neurodegeneration

    US20140378548A1

  • Precision Medicine for Schizophrenia and Psychotic Disorders: Objective Assessment, Risk Prediction, Pharmacogenomics, and Repurposed Drugs

    US20220403469A1